Circulating Tumor Cells
Conditions
Keywords
Non small-cell lung cancer, Circulating tumor cells, Carcinoembryonic antigen, Cytokeratin
Brief summary
The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients
Detailed description
In spite of technological advantages in diagnosis and treatment, lung cancer remains one of the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response to treatment. The objective of the study is to associate the number of circulating tumor cells (CTC) before and after treatment and correlate it with tumor response rate, progression-free survival and overall survival.
Interventions
None listed
Sponsors
National Institute of Cancerología
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histopathologic diagnosis of non small-cell lung cancer * Clinical stage IV * ECOG functional status 0 or 1 * No renal function alteration (GFR \>50%) * No hepatic function alteration (ALT and AST less than 2 times its normal value) * Leucocytes more than 2,000/mcl * Hemoglobin more than 10mg/dL * Platelets more than 100,000/mcl
Exclusion criteria
Non-advanced disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate, progression-free survival and over-all survival | 4 years |
Secondary
| Measure | Time frame |
|---|---|
| Quantification of CTCs | 4 years |
Countries
Mexico
Contacts
Primary ContactOscar Arrieta, MD
Outcome results
None listed